Paul N. Reynolds

Paul N. Reynolds

Auto-generated profile, based on publicly available information

Paul N. Reynolds

University of Adelaide, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
ARAnn M. Reynolds
Ann M. Reynolds
WXWei Xia
Wei Xia
MHMark D. Holmes
Mark D. Holmes
SHSandra J. Hodge
Sandra J. Hodge
SDSergei Danilov
Sergei Danilov
PRPaul N. Reynolds
Paul N. Reynolds
Idiopathic pulmonary arterial hypertension (PAH) is characterized by proliferation of pulmonary vascular endothelial and smooth muscle cells causing increased vascular resistance and right heart failure. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are believed to cause the familial form of the disease. Reduced expression of BMPR2 is also noted in secondary PAH. Recent advances in the therapy of PAH have improved quality of life and survival, but many patients continue to do poorly. The possibility of treating PAH via improving BMPR2 signaling is thus a rational consideration. Such an approach could be synergistic with or additive to current treatments. We developed adenoviral vectors containing the BMPR2 gene. Transfection of cells in vitro resulted in upregulation of SMAD signaling and reduced cell proliferation. Targeted delivery of vector to the pulmonary vascular endothelium of rats substantially reduced the pulmonary hypertensive response to chronic hypoxia, as reflected by reductions in pulmonary artery and right ventricular pressures, right ventricular hypertrophy, and muscularization of distal pulmonary arterioles. These data provide further evidence for a role for BMPR2 in PAH and provide a rationale for the development of therapies aimed at improving BMPR2 signaling.

24 November 2020 in Respirology
Verified
Journal Article
Open access
PDF file
AJAdelle S. Jee
Adelle S. Jee
RSRobert Sheehy
Robert Sheehy
PHPeter Hopkins
Peter Hopkins
TCTamera J. Corte
Tamera J. Corte
CGChristopher Grainge
Christopher Grainge
GKGregory J. Keir
Gregory J. Keir
Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from limited, non‐progressive lung involvement, to fulminant, life‐threatening disease. Given the potential for major adverse outcomes in CTD‐ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD‐ILD. Autoimmune‐mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD‐ILD. However, the natural history of CTD‐ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD‐ILD and, where available, evidence‐based, disease‐specific approaches to treatment have been provided.

25 January 2018 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
HJHelen E. Jo
Helen E. Jo
IGIan Glaspole
Ian Glaspole
YMYuben Moodley
Yuben Moodley
SCSally Chapman
Sally Chapman
SESamantha Ellis
Samantha Ellis
TCTamera J. Corte
Tamera J. Corte
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of unknown cause. The advent of anti-fibrotic medications known to slow disease progression has revolutionised IPF management in recent years. However, little is known about the natural history of IPF patients with mild physiological impairment. We aimed to assess the natural history of these patients using data from the Australian IPF Registry (AIPFR). Using our cohort of real-world IPF patients, we compared FVC criteria for mild physiological impairment (FVC ≥ 80%) against other proposed criteria: DLco ≥ 55%; CPI ≤40 and GAP stage 1 with regards agreement in classification and relationship with disease outcomes. Within the mild cohort (FVC ≥ 80%), we also explored markers associated with poorer prognosis at 12 months. Of the 416 AIPFR patients (mean age 70.4 years, 70% male), 216 (52%) were classified as ‘mild’ using FVC ≥ 80%. There was only modest agreement between FVC and DLco (k = 0.30), with better agreement with GAP (k = 0.50) and CPI (k = 0.48). Patients who were mild had longer survival, regardless of how mild physiologic impairment was defined. There was, however, no difference in the annual decline in FVC% predicted between mild and moderate-severe groups (for all proposed criteria). For patients with mild impairment (n = 216, FVC ≥ 80%), the strongest predictor of outcomes at 12 months was oxygen desaturation on a 6 min walk test. IPF patients with mild physiological impairment have better survival than patients with moderate-severe disease. Their overall rate of disease progression however, is comparable, suggesting that they are simply at different points in the natural history of IPF disease.

25 July 2022 in Respirology
Verified
Journal Article
Open access
SHStephen Humphries
Stephen Humphries
JMJohn Mackintosh
John Mackintosh
HJHelen E. Jo
Helen E. Jo
SWSimon L. F. Walsh
Simon L. F. Walsh
MSMario Silva
Mario Silva
TCTamera J. Corte
Tamera J. Corte
Background and objective: Prediction of disease course in patients with progressive pulmonary fibrosis remains challenging. The purpose of this study was to assess the prognostic value of lung fibrosis extent quantified at computed tomography (CT) using data‐driven texture analysis (DTA) in a large cohort of well‐characterized patients with idiopathic pulmonary fibrosis (IPF) enrolled in a national registry.Methods: This retrospective analysis included participants in the Australian IPF Registry with available CT between 2007 and 2016. CT scans were analysed using the DTA method to quantify the extent of lung fibrosis. Demographics, longitudinal pulmonary function and quantitative CT metrics were compared using descriptive statistics. Linear mixed models, and Cox analyses adjusted for age, gender, BMI, smoking history and treatment with anti‐fibrotics were performed to assess the relationships between baseline DTA, pulmonary function metrics and outcomes.Results: CT scans of 393 participants were analysed, 221 of which had available pulmonary function testing obtained within 90 days of CT. Linear mixed‐effect modelling showed that baseline DTA score was significantly associated with annual rate of decline in forced vital capacity and diffusing capacity of carbon monoxide. In multivariable Cox proportional hazard models, greater extent of lung fibrosis was associated with poorer transplant‐free survival (hazard ratio [HR] 1.20, p < 0.0001) and progression‐free survival (HR 1.14, p < 0.0001).Conclusion: In a multi‐centre observational registry of patients with IPF, the extent of fibrotic abnormality on baseline CT quantified using DTA is associated with outcomes independent of pulmonary function.

11 January 2024 in Respirology
Verified
Journal Article
Open access
JMJohn Mackintosh
John Mackintosh
GKGregory Keir
Gregory Keir
LTLauren K. Troy
Lauren K. Troy
AHAnne E. Holland
Anne E. Holland
CGChristopher Grainge
Christopher Grainge
TCTamera J. Corte
Tamera J. Corte
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.

26 January 2016 in Respirology
Verified
Journal Article
Closed access
PDF file
RHRebecca L. Harper
Rebecca L. Harper
ARAnn M. Reynolds
Ann M. Reynolds
Claudine BonderClaudine Bonder
Claudine Bonder
PRPaul N. Reynolds
Paul N. Reynolds